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Abstract: Sipuleucel-T is an autologous cell immunotherapy for castrate-refractory prostate 
cancer, with US Food and Drug Administration (FDA) approval in asymptomatic or minimally 
symptomatic prostate cancer. In this review we address the background of prostate cancer 
incidence and other available therapy onto which sipuleucel-T treatment has been added, with 
discussion of hormone-therapy, chemotherapy, and other investigational immunotherapies. 
The sipuleucel-T manufacturing process, toxicity and clinical benefit are reviewed, along with 
an examination of the issue of clinical benefit to survival, independent of apparent changes of 
prostate-specific antigen (PSA) levels. Sipuleucel-T therapy is appraised from clinician, patient 
and immunotherapeutic perspectives, with reference to the clinical data from the pivotal trial, 
the mechanism of action, and the treatment process.
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Medical management directions  
for advanced prostate cancer
The number of people impacted by the burden of prostate cancer is staggering. With 
tens of millions of men undergoing screening tests, over 2 million US men alive with 
a history of prostate cancer in 2007, over 200,000 annual new diagnoses and 32,000 
US deaths in 2010,1 prostate cancer continues to have a high profile in worldwide 
oncology and in US healthcare. Fortunately, many cases are biologically indolent, or 
do not require treatment because they occur in older men for whom there is a lower 
prostate-cancer-specific risk relative to non-cancer risk of mortality. The subset of 
patients at high risk for prostate-cancer-specific mortality remains a complex group, 
for whom the development of better therapies continues in several directions. Among 
these treatments is immune therapy, studied in many variations within prostate cancer 
and across oncology. With the 2010 US Food and Drug Administration (FDA) approval 
of the first cellular therapy and the first immune therapy for this disease, sipuleucel-T 
(Provenge™, Dendreon, Seattle, WA), prostate cancer may now be one of the main tar-
gets for clinical, FDA-approved application of the potent immunotherapy paradigm.
We review here the background of advanced prostate cancer biology and treatment 
options, other immunotherapy directions, and clinical trials undertaken in the develop-
ment of sipuleucel-T. We also present the view of patients, the public and oncologists 
regarding this new approach to treating prostate cancer.OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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Defining sources of heterogeneity
Heterogeneity is a major characteristic of patients with a 
diagnosis of prostate cancer. The age at presentation covers 
decades, and the incidence and comorbidities increase with 
age.2 The mean number of comorbidities in the NIA/NCI 
SEER Study sample for those aged 55–64 years is 2.9; for 
65–74 years, it is 3.6, and 75+ years is 4.2.3 The higher relative 
contribution of comorbidities to mortality in older men with 
prostate cancer should be factored into treatment planning, 
particularly for lower-risk and localized cases. That risk can 
be estimated through Gleason scores, prostate-specific antigen 
(PSA) level, and localized tumor-stage ratings for locally 
directed treatments.4 Differences of incidence of prostate 
cancer in racial groups are well known. African Americans 
have a 2.5 times higher incidence and over twice the mortality 
rate of Caucasian men;1,5,6 this is not fully explained by the 
presence of comorbidities, lack of PSA screening, or access to 
health care. Genetic factors may be involved,7 but to date there 
is no direct linkage of genetic studies to therapy choices.
Both tumor- and patient-related factors affect treatment. 
As in much of oncology, a variety of treatments are available 
and a decision in favor of any particular option takes into 
account the estimated likelihood of dying from cancer with-
out early treatment, treatment-related mortality and morbid-
ity, costs, convenience and patient preference. Sipuleucel-T 
is an expensive treatment, with few immediate side effects. 
Few data address outcomes based on patient characteristics 
or preferences, and health-related quality-of-life compari-
sons between various treatments are sparse.8 Patients make 
decisions largely on the basis of information received from 
their physicians.9,10 For many treatment decisions, there is 
no oncologically absolute standard.
Contemporary options
Besides sipuleucel-T, current options in prostate cancer 
treatment include active surveillance, radical prostatectomy, 
radiation therapy (external-beam radiation or interstitial 
brachytherapy), androgen deprivation, anti-androgens, and 
cytotoxic chemotherapy drugs. Targeted drugs are in wide 
development, but remain experimental for this diagnosis. 
We will discuss the contemporary medical management of 
prostate cancer in the following sections, with more detail 
about novel immunotherapy (Table 1).
Conventional hormone suppression  
and variations
Gonadotropin releasing hormone (GnRH) analogs are used 
widely to achieve decreased testosterone levels, termed 
medical castration. Successful use of leuprolide in prostate 
cancer was reported in 1982,13 and US FDA approval for 
advanced prostate cancer treatment was obtained in 1985. 
The agonist drugs (such as goserelin acetate, different leu-
prolide formulations, or triptorelin) bind to GnRH receptors 
on the pituitary gland, initially causing release of luteinizing 
hormone (LH) and follicle stimulating hormone (FSH) which 
in turn increase testosterone production from the Leydig 
cells in the testes resulting in a “testosterone flare” lasting 
a week or two. There is eventually downregulation of those 
GnRH receptors, followed by decreasing FSH and LSH, and 
consequently suppressed testicular testosterone production, 
down to castrate levels by about 3–4 weeks. A peripheral 
anti-androgen, such as bicalutamide, may be co-administered 
for the first few weeks to avoid symptoms from a tumor flare 
caused by the transient testosterone increase.
The GnRH analog antagonist drugs were developed 
much later. These bind (block) at the pituitary GnRH 
receptor and thus directly decrease FSH and LH and tes-
tosterone, without a flare phase. Abarelix was voluntarily 
withdrawn from the US market, due to a low but detectable 
incidence of anaphylaxis. Degarelix was approved by US 
FDA in 2008; it induced testosterone suppression by day 
3 in .90% of patients compared to none with leuprolide; 
at 14 and 28 days median PSA levels were significantly 
lower in the newer drug group; and both testosterone and 
PSA suppression were maintained throughout the 1 year 
study period.11 In a recent preliminary update on the ongo-
ing CS21A study12 for patients receiving degarelix there 
was a significantly better PSA progression-free survival 
(PFS) during year 1 compared to leuprolide treatment. 
More mature data to directly address a relative clinical 
benefit (contrasted with an isolated PSA-benefit) for GnRH 
antagonists are still needed.
Testosterone suppression, whether via surgical castration 
or medical treatment, has many known potential adverse 
effects. Some are directly related to androgen deprivation, 
such as vasoactive symptoms (hot flashes), loss of libido, 
impotence, fatigue, anemia, changes in body composition 
(less muscle, more fat), or gynecomastia, as well as more 
insidious effects such as insulin resistance, metabolic syn-
drome, hyperlipidemia, cardiovascular disease, accelerated 
loss of bone density (osteopenia, osteoporosis), mood or 
cognitive changes.14,15 There is a variably negative impact 
on quality of life. Despite this, testosterone suppression, 
usually with GnRH agonists, remains the first line hor-
monal therapy for advanced prostate cancer.16 The subjects 
in the   sipuleucel-T pivotal trial, discussed in detail below, OncoTargets and Therapy 2011:4
Table 1 A variety of potential therapies, organized by mechanism
Pathway Marketed agents Investigational agents and those  
with recent approval in other  
cancer indications
Hormonal GnRH agonists (goserelin**, leuprolide)
GnRH antagonists (degarelix; abarelix [withdrawn from US market])
Anti-androgens (bicalutamide, nilutamide, flutamide)
estrogens (estradiol, diethylstilbestrol [DeS])
Testosterone synthesis inhibitors: Ketoconazole, abiraterone*
Herbal mixtures (eg, Prostasol™)
MDv3100 
TAK-700
Microtubule-directed  
chemotherapy
Docetaxel* 
Cabazitaxel* 
vinblastine
estramustine
Paclitaxel
epothilone analogs
eribulin mesylate
Alternative taxane formulations
DNA-damaging agent  
chemotherapy
Mitoxantrone 
Cyclophosphamide
Many investigational drugs
immunotherapy Sipuleucel-T ipilumimab and many others
Targeted therapy (none) Negative Phase iii trial for sunitinib 
Negative Phase iii trial for  
bevacizumab + docetaxel vs docetaxel
Radioactive isotopes Samarium 
Strontium
Radium (Alpharadin™)
Note: *Survival benefit demonstrated in Phase III study.
Abbreviation: GnRH, gonadotropin-releasing hormone.
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had   prostate cancer with progression despite testosterone 
  suppression (castrate-refractory prostate cancer, [CRPC]).
Anti-androgens
Anti-androgens inhibit androgen binding to the androgen 
receptor (AR) as well as inhibiting androgen-independent 
activation of the AR protein, a DNA-binding transcription 
factor. The non-steroidal drugs flutamide, bicalutamide and 
nilutamide are approved for use in the US while the steroid 
cyproterone acetate is also approved for use in Europe. When 
compared to medical or surgical castration, anti-androgen 
monotherapy showed inferior survival and time to progres-
sion and for this reason is not routinely used.17 Sipuleucel-T in 
combination with anti-androgen monotherapy was not stud-
ied in the pivotal trial. Although anti-androgens are generally 
well tolerated, some adverse effects of nonsteroidal anti-
androgens include diarrhea and gynecomastia. Diminished 
visual adaption to darkness is exclusive to nilutamide.
Sequential use of distinct hormonal therapies is often   useful. 
Addition of anti-androgen (combined androgen blockade) to 
address progression on GnRH analog-mediated testosterone 
suppression may result in PSA control, for some. For patients 
who show PSA-progression after combined androgen blockade, 
anti-androgen withdrawal can induce a sustained PSA response 
for some.18 The hypothesis behind the withdrawal is that the anti-
androgen itself was stimulating the AR, which may have mutated. 
The in vitro molecular effects of different   anti-  androgens on AR 
can vary.19 Novel anti-androgens are discussed below. Trial 
designs are similar to that of sipuleucel-T.
Some preclinical data suggest that intermittent androgen 
deprivation, instead of conventional continuous suppres-
sion which mimics surgical castration, may delay CRPC 
development.20 Also, both drug costs and management of 
comorbidities could decrease with less suppression.21 Most 
available clinical data on intermittent androgen deprivation 
are from small Phase II studies,22–24 addressing diverse popu-
lations with localized, locally advanced, metastatic disease 
or biochemical recurrence, using a variety of drug-holiday 
strategies. From the recently presented results of the SWOG 
JPR7 trial (1,386 patients)25 the intermittent schedule was 
non-inferior compared with continuous androgen deprivation 
for PSA recurrence after definitive treatment, with a median 
overall survival (OS) of 8.8 vs 9.1 years. The intermittent arm 
had fewer hot flashes but no difference in other adverse events 
such as myocardial events or osteoporotic fractures. The 
EC507 trial26 also found no difference in time to progression 
for patients with PSA relapse after radical prostatectomy, but 
significantly fewer side effects were reported. Mature data 
are awaited from the SWOG 9346 study comparing these 
approaches in metastatic prostate cancer.
Currently, intermittent suppression is considered in 
selected patients. The testing of sipuleucel-T was focused OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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on patients already refractory to hormone therapy, whether 
the prior testosterone suppression had been intermittent or 
continuous. While the scale of these intermittent hormone 
therapy trials, in terms of number of patients enrolled, is 
comparable to the sipuleucel-T pivotal trial, the time-scale 
for the duration of active use of the treatment being studied 
is much longer. Similarly, the survival times and follow-up 
duration are much longer than all the studies on CRPC 
patients, where a median OS endpoint is observed in about 
the 12–24 month range.
Other drugs affecting the hormone axis
Ketoconazole is an antifungal agent which is a nonspecific 
weak inhibitor of cytochrome CYP17, an enzyme of andro-
gen biosynthesis. Administered at doses higher than used 
for antifungal therapy, with hydrocortisone (because of the 
side effect of cortisol suppression), ketoconazole can effect 
further decrease of testosterone and then a PSA response in 
as many as 30%–60% of selected patients with PSA pro-
gression, with a variable duration of months to years. Some 
limitations include potential side effects such as nausea, 
anorexia, hepatic dysfunction, nail dystrophy or rashes.27,28 
Second-generation androgen biosynthesis inhibitors such as 
abiraterone, discussed below, may overcome some of these 
limitations.
Corticosteroids such as prednisone and dexamethasone 
are also active in prostate cancer. These have been used as 
partner drugs for docetaxel, mitoxantone, and abiraterone, 
or as single agents, with a potential favorable impact on 
bone pain, and on drug tolerability. One trial reported a PSA 
response rate of over 60%,29 but a much lower response rate 
and duration of corticosteroid monotherapy is the general 
experience. In contrast, most immunotherapy approaches, 
including sipuleucel-T, are tested with a specific, system-
atic exclusion to address the immunosuppressive potential 
of corticosteroids, particularly on lymphocyte activation, 
proliferation and survival. However this makes it harder to 
understand how or when combinations with corticosteroids, 
should be used with sipuleucel-T.
Cytotoxic chemotherapy drugs
Docetaxel (Sanofi-Aventis, Paris, France) was the first 
systemic chemotherapy specifically showing an improved 
median survival in two Phase III studies compared to 
mitoxantrone.30–32 The reference treatment plan, mitoxan-
trone, in combination with corticosteroid, was previously 
shown to have a quality of life benefit.33,34 The similari-
ties and differences of the groups being treated, compared 
with the patients in the sipuleucel-T trial, can be debated. 
While the sipuleucel-T trial was limited to minimally 
symptomatic patients, both asymptomatic and symptomatic 
patients were the subject of the positive trials that helped 
to establish docetaxel, once every three weeks, with con-
current daily oral prednisone, as the main initial cytotoxic 
chemotherapy in use for progressive CRPC. As discussed 
below, many of the patients in the sipuleucel-T trials did 
subsequently receive docetaxel chemotherapy. The first 
second-line-chemotherapy with a positive Phase III trial, 
specifically tested in post-docetaxel CRPC patients, is caba-
zitaxel (Sanofi-Aventis, Paris, France).35 Patients who had 
generally initially responded but subsequently progressed 
on docetaxel were randomized against mitoxantrone and 
a significant overall survival advantage was observed. The 
safety and toxicity features of the new taxane were appre-
ciable, with grade 3 or 4 neutropenia in 82% patients, febrile 
neutropenia in 7.5% patients, diarrhea in 6% of patients and 
death related to adverse events in 5% of patients.
Increases in median survival time observed in these tax-
ane studies can be compared to those observed in the pivotal 
trial of sipuleucel-T. In the SWOG 9916 trial, survival was 
17.5 months in the docetaxel arm vs 15.3 for those random-
ized to mitoxantrone; in the TAX327 trial, 19.3 months vs 
16.3 (comparing once-every-3-weeks docetaxel to mitox-
antrone); and in the TROPIC (cabazitaxel vs mitoxantrone) 
trial, 15.1 vs 12.7 months.30–32,35 Some recent cytotoxic 
chemotherapy-based Phase III trials, conducted on a similar 
multinational scale with about 1000 patients, that did not 
demonstrate a survival advantage, include docetaxel without 
or with bevacizumab36 and satraplatin plus prednisone vs 
prednisone alone.37
Newer hormone-pathway drugs
Every new drug development is awaited by the prostate can-
cer community, and represents a challenge to the clinician for 
use of the new drug instead of those already on the market. 
Sipuleucel-T is now part of that dynamic, with respect to 
newer hormone-pathway drugs. MDV3100 (Medivation, 
Inc, San Francisco, CA) is a novel small-molecule selec-
tive AR antagonist that has three complementary actions 
on cancer cells: blockage of testosterone binding to AR; 
impediment of AR nuclear translocation (movement from 
cytoplasm to nucleus of activated, dimerized AR); and inhi-
bition of DNA binding by AR.38 The latter two mechanisms 
are not found in the marketed nonsteroidal anti-androgens 
and cyproterone acetate. MDV3100 also lacks AR agonist 
activity. Tested in vitro, MDV3100 slowed growth and OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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killed   castration-resistant and bicalutamide-resistant prostate 
cancer cells.38 Phase II data were encouraging, with .50% 
PSA responses in 56% of the CRPC patients, median time 
to radiologic progression of 10.8 months, decrease in circu-
lating tumor cell (CTC) counts, and favorable side effects 
(dominated by fatigue) which responded to dose reduction. 
The AFFIRM trial (NCT 00974311) in CRPC patients is a 
pivotal trial vs placebo, after docetaxel treatment, and has 
completed accrual. The PREVAIL trial (NCT 01212991) is 
ongoing in chemotherapy naïve CRPC subjects.
Abiraterone (Centocor Ortho Biotech Inc, Horsham, 
PA) is an inhibitor of the cytochrome enzyme CYP17, as 
is ketoconazole, but is more potent, and also inhibits the 
cytochrome 17–20 lyase.39 Besides decrease of systemic 
testosterone, intratumoral testosterone synthesis may be 
suppressed as well.40 Compared to ketoconazole hormonal 
side-effects, treatment with abiraterone has less cortisol sup-
pression, but more aldosterone formation. Early phase studies 
were promising, with 67% of patients demonstrating .50% 
declines in PSA,41 and in the post-docetaxel setting, 43%–51% 
achieving that PSA benchmark.42,43 Additionally, there were 
partial radiographic responses in 37.5%.41 Results from the 
pivotal Phase III demonstrated a median OS of 15.8 months 
with abiraterone vs 11.2 months with placebo.44 It now has 
US FDA approval for use in patients with metastatic CRPC 
who have received prior docetaxel treatment. Results of 
another Phase III study (COU-AA-302, NCT00887198) of 
abiraterone vs placebo for chemotherapy naïve metastatic 
CRPC are keenly awaited.
Other novel hormonal agents in development include 
TOK-001 (Tokai Pharmaceuticals, Cambridge, MA), which 
is also a potent blocker of the AR, and TAK-700 (Takeda 
Pharmaceutical Company, Osaka, Japan), another inhibitor 
of androgen synthesis.44
Novel cytotoxic drugs
Sipuleucel-T can be contrasted with the regimens for treat-
ment with cytotoxic drugs, looking at cumulative infusions, 
burden of side effects, duration of active treatment and 
drug expense. The process of developing algorithms for 
strategic sequencing or combination of new agents, includ-
ing sipuleucel-T and other novel immunotherapies remains 
incomplete.
Balancing the experiences of positive Phase III trials using 
cytotoxic drugs (mitoxantrone, docetaxel, cabazitaxel)30–34 
against negative ones,36,37(docetaxel with bevacizumab, 
satraplatin) there is still continued interest in the development 
of chemotherapeutic treatments while recognizing that some 
patients are averse to intravenous treatment or risk-averse to 
fatigue or other typical side effects. The need for ongoing 
randomized trials is underscored, even in the face of encour-
aging Phase II, nonrandomized, PSA-based results.
One example of a cytotoxic drug category with new 
application in anti-prostate-cancer therapy is the epothilones, 
such as patupilone and ixabepilone. These have a mechanism 
of action similar to that of taxanes but differ in their bind-
ing and interaction with β-tubulin.46 A randomized study 
of ixabepilone against mitoxantrone (with cross over from 
mitoxantrone to the new drug allowed) was reported, with 
the median survival, PSA responses and partial responses 
similar in both groups.47
Development of sipuleucel-T
Concepts of antigen presentation  
and immune activation
The central goal of immunotherapy is activation of an 
immune response directed against tumor cells while over-
coming tumor-induced tolerance.48 Prostate cancer has a 
few characteristics that make immunotherapy attractive. 
These are:
1.  The presence of a variety of tumor-associated antigens 
such as prostate-specific antigen (PSA), prostatic acid 
phosphatase (PAP), prostate-specific membrane antigen 
(PSMA), and others that are cancer- or organ-specific.
2.  It is, at least initially, a slow-growing disease thus offering 
enough time for the stimulated immune system to gener-
ate an antitumor response while overcoming immunosup-
pressive factors.48,49
3.  Spontaneous autoantibodies, as shown by phage protein 
microarrays, indicate that a nascent immune response may 
be already present, with the potential to be amplified.50
4.  The prostate is a dispensable organ, therefore the use 
of passive immunotherapy is relatively safe, because 
any autoimmunity generated would have little, if any, 
consequence to the patient.
To be effective, cancer vaccines enhance activation 
of tumor-specific T-cells with concurrent reduction of 
  immunosuppression.51 T-cells attack tumor cells and induce 
regression. Natural killer (NK) cells can also mediate 
anticancer immunity.52 Data suggest a positive correlation 
between the presence of tumor infiltrating CD8+ T-cells 
and good prognosis in various types of cancer.51 There are 
several intratumoral mechanisms that impair immune attack 
including class I HLA downregulation (corresponding to 
decreasing susceptibility to CD8 CTL lysis),53–55 PD-1 ligand 
expression,56,57 and Fas-ligand expression (each inducing OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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apoptosis or de-activation of infiltrating lymphocytes).58 
Tumor secretion of inhibitory cytokines, indoleamine 2,3-
dioxygenase59 and nitric oxide synthetase60,61 can also protect 
tumors from attack. Local expression of cytokines including 
vascular endothelial growth factor (VEGF), interleukin-10 
(IL-10), and tumor growth factor beta (TGF-β), which induce 
a tolerogenic phenotype in antigen presenting cells (APC), 
may be examples of general tumor anti-immune pathways.
The goal of anticancer vaccines is thus modification of the 
interaction between tumor cells and the immune system so 
the latter will escape suppression. In the context of an estab-
lished cancer, an existing, pathologic self-tolerance must be 
broken. In order to produce an effective immune response, 
selection of the appropriate antigen needs to be combined 
with activation of APCs so that the host’s immune system 
can then mediate the antitumor effect.
APCs are responsible for uptake, processing, and presen-
tation of antigens to immune system T cells in the context of 
HLA class I and class II molecules.62 Dendritic cells (DC) are 
considered to be the most potent APCs with powerful T cell 
priming properties. They also have the capacity to activate 
naïve and memory B cells as well as NK cells and T cells.63 
Since antigen-loaded DC can elicit a beneficial cellular 
immune response, vaccines based on DC have been used 
for the development of cell-based therapies. Sipuleucel-T is 
based on directly loading the autologous APC and DC with 
the prostatic acid phosphatase (PAP) antigen.
Methods of clinical immune activation
Dendritic cells have proven to be a good route for the vaccina-
tion process.63 Data from murine models supported early phase 
trials using DC loaded with an engineered antigen-  cytokine 
fusion protein (PA2024) consisting of PAP and granulocyte-
macrophage colony-stimulating factor (GM-CSF), for which 
there are receptors on APC.64 This combination induces strong 
cellular immune responses in vivo to tissues and tumors that 
express PAP. The role of GM-CSF is a key factor for activat-
ing APC since dendritic cells pulsed without GM-CSF (PAP 
alone) elicited significantly weaker immune responses.62 Data 
also demonstrated that isolated DC could be exposed to tis-
sue- or disease-associated antigens in vitro and re-infused to 
stimulate immunity to those antigens,65,66 showing measurable 
antitumor cellular immune responses.
Sipuleucel-T takes advantage of DC properties to make 
PAP a more attractive antigen to the immune system. The 
manufacture of sipuleucel-T includes the collection of den-
dritic cells from prostate cancer patients and activation ex 
vivo with recombinant fusion protein PA2024. This PA2024 
consists of PAP linked to GM-CSF. The process itself is 
proprietary and is performed in a central facility for all the 
procedures. First the patient has an apheresis, and the bag 
with the collected leukocytes (unprocessed white blood cells) 
is shipped to the Dendreon central facility. The product is 
prepared from the collected cells by co-culturing APC for 
36–44 hours in media containing PA2024. When the product 
(white blood cells, now sipuleucel-T) is certified, it is trans-
ported back to the local center as infusible autologous cells. 
As specified by the manufacturer Dendreon, the infusible 
product contains APC (at least 50 million CD54+ cells) and 
also 60%–70% lymphocytes and other mononuclear cells. 
Both the DC and the lymphocytes may contribute to, or con-
stitute, the clinical activity. Patients will have three apheresis 
and infusions, generally at 2-week intervals. The use of a 
series of three may be of significance (vs serial application 
of cells from a single apheresis), because it allows for a 
boost-and-prime paradigm, with direct analogy to classical 
vaccination.67
Off-the-shelf vs custom manufacturing
Most new drugs, particularly immunotherapeutics, face chal-
lenges to their acceptance. Reasons include high production 
costs, limited resources for distribution, and resistance from 
the medical community because of modifications needed to 
deliver the drug, or a low level of confidence in the novel 
mechanisms of action. The patients’ perspective on the drug 
or drug class must also be considered – for many “immuno-
therapy” has a desirable cachet that “chemotherapy” cannot 
ever achieve. Convenience and simple administration of 
the treatment are essential. Despite the challenges, cancer 
vaccines provide an attractive option for patients given their 
outpatient administration and lack of common side effects 
associated with cytotoxic chemotherapeutics.
Autologous tumor vaccines are personalized products 
that contain a specific tumor-associated antigen. The tailored 
production of autologous vaccines, like sipuleucel-T, sacri-
fices the convenience and lower production costs associated 
with off-the shelf agents readily available for use. These 
factors may make custom production less attractive to the 
cost-conscious health-care environment. In addition, both 
autologous and allogeneic vaccines have shown remark-
able limitations in creating strong and durable immune and 
tumor responses.
Selection of a test-population
The selection of a sub-population of prostate cancer patients 
for Phase III trial testing has implications both for the chance OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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of observing a response, and for the definition of the popu-
lation for subsequent off-study clinical application. When 
using immunotherapy, one has to consider the underlying 
mechanisms driving the cancer and also the aging process 
of the patient’s immune system; these define different con-
trasting immune-contexts.68 Most prostate cancer patients 
are older men who have achieved an immune “maturity” 
which favors an inability to produce naïve T cells. This is, 
biologically, a contrast from in vivo testing in young mice. 
The effects prior treatment may have had on patients’ immune 
systems are also relevant, as well as the long duration of 
exposure of the immune system to the tumor. There may be 
opportunity for better or worse timing of the same treatment. 
In the   sipuleucel-T pivotal trial, some patients were previ-
ously treated with cytotoxic agents, potentially representing 
a population that is less able to benefit from immunotherapy 
when compared to treatment-naïve patients or even hormone-
sensitive patients in earlier stages of their disease.
The capacity of the immune system to tackle tumor cells 
may vary along with the disease course and is compromised 
by age.69,70 Assuming relevant increases of tumor toler-
ance during disease progression, it might be reasonable to 
introduce sipuleucel-T earlier in the course of the disease. 
There may be a population that might be more competent 
and fit to mount an immune response and take advantage of 
immune modulation, as compared to the population used in 
the pivotal trial.
Ultimately, the design of a pivotal trial represents a bal-
ance between the most urgent clinical need, the broadest 
market, and the best immunologic context. For the case of 
sipuleucel-T, several subset populations could be explored in 
future testing. For example instead of hormone-insensitive, 
minimally symptomatic patients, a study could focus on 
symptomatic, hormone sensitive prostate cancer patients 
(earlier in the disease course, but anticipating shorter 
hormone-response duration) where a larger clinical impact 
may be observed.
The process of defining clinical trial end points for 
a novel immunotherapy treatment can be difficult, since 
immediate regression of the tumor has not occurred. A sig-
nificant latency, dependent on the generation of the immune 
response must be allowed, in contrast to the direct anti-tumor 
activity of classic cytotoxic chemotherapies. This makes 
PSA-response or time to progression a difficult intermediate 
marker to correlate with overall survival. Maximal T-cell 
reactivity could take 8 to 10 weeks to achieve.71   Evaluating 
for TTP before or during this window may miss the poten-
tial immune antitumor effect. This factor may have been 
  illustrated when some patients developed progressive disease 
before the treatment achieved its biologic effects.71 Stable 
disease state, or a better response to chemotherapy after 
exposure to sipuleucel-T might be reasonable end points for 
future clinical trials. Evaluation and measurements of the 
immune response (that is, titers of antigen-specific T cells) 
might add to this data guiding the timing and administra-
tion of the sipuleucel-T, particularly in chemotherapy-naïve 
patients, or other contexts where the pace of potential clinical 
progression is slower. However, these surrogate endpoints 
cannot replace the survival comparison.
Monitoring the effect on PSA should also be considered as 
a reliable marker of tumor response in clinical trials, while rec-
ognizing its limitations, particularly in cases of high   Gleason 
scores (greater than 7). PSA level gives an early sign of drug 
utility and has particular relevance as a pharmaceutical drug 
development “signal” in prostate cancer   therapeutics.72 The 
potential for a disconnect between PSA-response and survival 
response remains a concern, however.
Biological diversity of prostate cancer in minority popu-
lations and younger patients is an area of ongoing study. As 
sipuleucel-T becomes more easily available, potential immu-
nologic response features in under-represented populations 
in the pivotal trials, such as African-Americans, and younger 
patients, could compared to the current, predominantly Cau-
casian and older population data. This will be of particular 
interest since prostate cancer is known to have a higher 
incidence in African-Americans. This can be related to the 
heterogeneity of cancer and also to cultural disparities.
Safety and efficacy  
and pivotal studies
Trial structure and inclusion criteria
The 2010 US FDA approval of sipuleucel-T was based on the 
pivotal trial Immunotherapy for Prostate Adenocarcinoma 
Treatment (IMPACT).73 This Phase III clinical trial was 
a double-blind, placebo-controlled, multicenter study that 
included asymptomatic or minimally symptomatic men with 
metastatic CRPC. As part of the inclusion criteria, patients 
with progressive disease (on imaging studies or based on PSA 
levels), with a PSA level of $5 ng/mL or more, and serum 
testosterone level of less than #50 ng/dL (castrate level) 
were eligible. Pretreated patients (18.2% had fewer than two 
chemotherapy treatments) and those with bone disease were 
included, but visceral metastasis was exclusionary.
Based on initial data from the earlier trial,71 patients with 
a Gleason score higher than 7 were initially excluded. After 
further analysis of that data demonstrated that the positive OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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treatment effect of sipuleucel-T was independent of Gleason 
score, the IMPACT protocol was amended and all histologic 
grades were included.
Five hundred and twelve patients were randomized in 
a 2:1 ratio to receive either sipuleucel-T (341 patients) or 
placebo (171 patients) administered intravenously at an 
interval of at least 2 weeks, for a total of three infusions.73 
Sipuleucel-T was prepared at a central facility as detailed 
on the package insert74 by culturing the leukocytes obtained 
from apheresis, processed to isolate APC and lymphocytes. 
These were cultured for 36–44 hours, at 37°C with media 
containing PA2024. For the study, each dose of sipuleucel-T 
or placebo contained a minimum of 40 million large cells 
expressing the co-stimulatory molecule CD54.73 This is 
slightly lower than is specified on the marketed product 
package insert. Study design allowed the crossover of 
patients with evidence of progression of disease to be part 
of an open-label salvage protocol and receive APC8015F, 
a product manufactured according to the same specifications 
as sipuleucel-T but prepared from cells cryopreserved at the 
time the placebo was prepared.73 The APC8015F product, 
therefore, would be administered at a point later in the disease 
course, and without the tandem collection of new apheresis 
product at intervals after the prior infusions.
Although the primary endpoint was OS, the objective dis-
ease time to progression (TTP) was monitored as well, using 
serial computed tomography (CT) at weeks 6, 14, 26, and 34 
and every 12 weeks thereafter and serial bone scans at weeks 6, 
10, 14, 18, 22, 26, and 34 and every 12 weeks thereafter. PSA 
levels were monitored at the same intervals as the CT scans.
Primary outcome
Overall survival, defined as the time from randomization 
until death from any cause, was the primary end point; time 
to objective disease progression was the secondary end point. 
The OS was analyzed with PSA levels and lactate dehydroge-
nase (LDH) adjustments, given their strong correlation with 
prognosis as shown in prior trials.71,75,76 A 4.1 month differ-
ence in median survival was seen in the experimental arm 
(25.8 for sipuleucel-T group vs 21.7 months in the placebo 
group; hazard rate 0.78, P = 0.03). The median time to objec-
tive disease progression was 3.7 months in the sipuleucel-T 
group and 3.6 months in the placebo group, which was not 
a statistically significant difference.
immunologic outcomes
Documentation of the immune responses during expo-
sure to sipuleucel-T provides some insight about the 
treatment   population. In some ways, this is a technical and 
not clinical perspective. However, the immune response pat-
terns define a direct connection to the proposed mechanism 
of action, and may be a direct connection to a next generation 
of immunomodulator, adjunctive drugs.
With the objective of analyzing humoral immune 
response, antibodies against the immunizing antigen PA2024 
and to PAP were evaluated, with a threshold titer of .1:400 
used to define a response. Anti-PA2024 was observed in 
66.2% of the patients in the sipuleucel-T arm compared 
to 2.9% in the placebo group. Titers greater than 400 for 
anti-PAP response were also greater in the treatment arm 
(28.5% vs 1.4% in the placebo group). Both differences were 
statistically significant.
T-cell proliferation responses against PA2024 were 
observed in 73.0% of the sipuleucel-T arm vs 12.1% in the 
placebo group. Similar results were obtained for responses 
to PAP with 27.3% in the experimental arm vs 8.0% in 
untreated population. These differences were also statisti-
cally   significant. When analyzed against the survival data, 
the antibody against PA2024 was significant (P , 0.001), 
and there was a trend in the response to the antibody to PAP 
(P = 0.08), but the week-6 T-cell proliferation did not define 
a difference. It is possible that a later, or different, or com-
bination immune assay would define the group with the best 
sipuleucel-T induced clinical response. Higher CD54+ cell 
count, higher total nucleated cell count, and CD54 upregula-
tion were all correlated with a better survival.75 This suggests 
that heterogeneity of the immunophenotype of the prostate 
cancer population, and heterogeneity of the incremental 
response could be defined and tested. The result of that testing 
could define a group for which there is a disproportionately 
better treatment-response.
Progression free survival – description 
and interpretation
The validity of clinical trials relies on a prospectively-defined, 
clinically relevant end point. As previously mentioned, OS 
was the primary end point of this pivotal trial. The crossover 
study design had potential contamination of the OS endpoint. 
Thus, even with the benefit of 4.1 months, no PFS impact was 
seen. The same pattern was previously seen by Small and 
colleagues in another randomized sipuleucel-T experiment, 
where TTP did not improve, but there was 4.5 months’ median 
OS advantage.71 The data from two Phase III trials were 
integrated,77 also with only a trend towards a delay of TTP.
The assumption used in developing the trial inclusion 
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progression of their disease could allow more time for the 
immunotherapy to work and slow the TTP, was not borne out. 
The TTP seems comparable to that in symptomatic patients.71 
Taken together, the conclusion is somewhat counterintuitive: 
the disease progression end point does not appear to be a 
reliable predictor of OS, for this population.73
Safety
The limited toxicity profile associated with immunotherapy 
is an attractive feature of many such treatments, at least for 
active immunizations. In these sipuleucel-T Phase III data, 
only three patients (0.9%) were unable to receive the three 
planned treatments due to infusion-related adverse events. 
Immune-related adverse events associated with   sipuleucel-T 
more than with placebo were chills, fever, headache, 
  influenza-like illness, myalgia, hypertension, hyperhidrosis, 
and groin pain. Most of these (except groin pain) resolved 
within 24–48 hours. These adverse effects were reported in 
65.2% of patients and were mostly grade 1 or 2. Grade 3 
adverse effects in the treatment arm were chills, fatigue, 
back pain, hypertension, hyperkalemia and muscle weakness. 
Only one grade 4 event due to catheter-associated infection 
was reported in the treatment arm. Grade 3 and 4 events 
were reported in 6.8% (23 patients) vs 1.8% (3 patients) in 
the placebo group.
Stroke was the most significant adverse effect reported 
with the use of sipuleucel-T. In the pivotal trial, 2.4% of 
patients (8 of the 338) in the sipuleucel-T arm developed 
cerebrovascular events. An FDA-mandated post-marketing 
evaluation of the frequency of that type of event is ongoing. 
The majority were nonfatal with a median interval from last 
infusion to event of 210 or 196 days (sipuleucel-T group or 
placebo).73
Selected other investigational 
immunotherapies
Both normal parenchymal prostate tissue and prostate cancer 
tissue bear antigens for which an anticancer immune attack 
with a clinically significant impact can be theoretically gen-
erated, without affecting other critical tissues. Sipuleucel-T, 
focused on PAP, is one of several different development 
efforts. However, the problem is not the issue of stimula-
tion of a response to a single protein, but rather of changing 
the patient’s general immune response in a way that can 
defeat the tumor-induced state of tolerance. Some clinical 
developments on the scale of the sipuleucel-T pivotal trial 
have been completed, or are anticipated in the   coming   
years.
Considering some investigational immunotherapy 
  strategies for which there is an application specifically in 
prostate cancer, and which are based on a restricted, specified 
antigen, there are several in current development. Two use a 
viral vector to deliver PSA to the immune system, based in 
one case on modified vaccinia and fowlpox viruses (PROS-
TVAC-VF) and in the other one an adenoviral vector.
PSA-viruses
A common concern with virally-based treatments is the 
safety of the parent virus; the vector is one for which the 
human immune system is competent to generate a protective 
response, eradicating infection. The genomes of two modi-
fied viral vectors, vaccinia and fowlpox, have been modified 
in Prostvac to contain the code for PSA, so that as virally 
infected cells are exposed to immune processing and attack, 
PSA will be treated as a viral protein for rejection, rather than 
a self-antigen leading to usual, but pathologic, tolerance. 
A further modification is the addition of a 3-part costimula-
tory transgene (designated as TRICOM). These code for 
the DC cell surface receptors B7-1[CD80], ICAM-1, and 
LFA-3, which have stimulatory effects on their T-lymphocyte 
ligands (B7.1:CD28, ICAM-1:LFA-1, and LFA-3:LFA-2 
[CD2]).78 In this way, the presentation of the PSA-associated 
antigenic peptides in HLA context will be stimulatory. The 
use of two different viruses was derived from a prime-boost 
strategy, with the modified vaccinia virus portion (rV-PSA-
TRICOM) used initially, and generating a strong immune 
response, including one directed to the viral antigens but not 
emphasizing the PSA. The later administration of the fowlpox 
virus (rF-PSA-TRICOM)79 serves as a boost, with a vector 
which dominates the immune response less. The vaccination 
schedule uses one dose of the rV-PSA-TRICOM and then 
subsequent monthly doses of rF-PSA-TRICOM.
Reported clinical trial results include some patients with 
PSA declines79 and across Phase II trials, a decline of PSA-
growth rate-constants.80 A current Phase II study randomizes 
CRPC subjects to treatment with docetaxel and prednisone 
with or without vaccination.
The development of clinical trials using the same vector 
framework (TRICOM, vaccinia, fowlpox), with other anti-
gens is ongoing. Among these is the muc-1 protein,81 which 
is a glycoprotein that has markedly different glycosylation 
patterns and antigenic features in cancer cells (as opposed 
to its physiologic expression), as a consequence of impaired 
glycosylation pathways. In addition to PSA, this antigen is of 
at least theoretical interest in prostate cancer immunotherapy, 
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that express abnormally glycosylated muc-1 protein. Other 
muc-1 directed prostate-cancer-specific immunotherapies 
are also in development, for example the nonviral, liposomal 
product L-BLP25.82
A modified adenovirus (Ad/PSA) was tested in a Phase 
I trial by Lubaroff et al in Iowa. The vector itself may have 
a capacity for generating a stronger anti-PSA response than 
the pox virus vectors.83 The product showed good safety 
experience, and a third of patients (34%) had generation of 
PSA antibodies, two-thirds (68%) with increased detectable T 
lymphocytes with anti-PSA specificity, and half (48%) with 
apparent declines of PSA doubling time.83 Further clinical 
testing is ongoing, comparing vaccine treatment without 
or with hormone suppression (NCT00583752) or in CRPC 
(NCT00583024).
PSMA
Prostate specific membrane antigen, PSMA, is not lim-
ited to prostate tissue. Despite the word “specific” in its 
name, PSMA is distributed both in prostate cancer84 and 
in the endothelium of non-prostate cancers.85 Both histo-
logic sites of PSMA are of interest for the development 
of anti-PSMA directed cancer therapy. The development 
of a spectrum of approaches encompasses both passive 
targeting with toxins, viruses or radioactive drugs, and 
active immunization with proteins and peptides.53,86 The 
DCvax product is one that was developed in early phase 
clinical trials, a decade ago.87 The process of preparation 
has some parallels to sipuleucel-T. Leukapheresis was 
used to obtain a DC product, for each patient, and these 
DC were pulsed with peptides derived from PSMA, and 
then re-infused again at intervals. The data from some of 
these trials describe some PSA responses,87 but no Phase 
III trial was conducted. Whether the successful marketing 
of sipuleucel-T as an autologous DC vaccine will be a 
catalyst for the development process for other autologous 
dendritic cell vaccines using PSMA or other antigens 
remains to be seen.53 The BPX-101 product was recently 
reported in a clinical trial with some clinical responses and 
PSA regression. It consists of autologous PSMA-loaded 
dendritic cells that are injected intradermally, followed 
by a dendritic cell activating drug, AP1903. (Bellicum 
Pharmaceuticals, Houston, TX).88
Our group has developed a clinical trial using peptides 
that represent epitopes of the protein PSMA and the pro-
tein TARP (TCR [T cell receptor] gamma alternate read-
ing frame protein), that can associate with HLA-class I 
and class II-proteins and is administered in conjunction 
with the toll-like receptor-3 (TLR-3) agonist poly IC-LC, 
with the objective of demonstrating immune response 
toward those epitopes. (NCT00694551). No results have 
been presented.
Tumor cell vaccines
There are many immunologic details that define distinc-
tions among vaccines using tumor cells vs those using 
isolated peptides or proteins. Whole cell vaccines have 
a broad array of antigens, which could induce a more 
potent reaction, but the particular cancer-related antigens 
are diluted by other tumor proteins. Another concern is 
that some component of the tumor cell proteins, such as 
matrix metalloproteinases, could actually mediate immune 
tolerance.89
A tumor cell anticancer vaccine which had two Phase 
III trials that were contemporary with the sipuleucel-T 
trial73,74,77 was GVAX (CellGenesys, South San Francisco, 
CA). This off-the-shelf product consists of two human 
allogenic prostate cancer cell lines (LnCAP and PC-3). 
The cell lines were modified further to produce GM-CSF, 
which should cause regional dendritic cells to be acti-
vated at injection sites, with a variety of relevant antigens 
obtained from the tumor cell material, including PAP (as 
emphasized in sipuleucel-T), PSMA, PSA, and others.90,91 
GM-CSF gene transduced cell line vaccines allow cross 
priming by avoiding the requirement for human leukocyte 
antigens (HLA)/major histocompatibility complex match-
ing between the cell lines and the patient. In contrast with 
sipuleucel-T, GVAX is consider to prime the T-cell to have 
an antitumor response against a broader range of tumor 
associated antigens, but this is limited by the capacity of 
the host and the host’s antigen presenting cells to mount a 
competent immune response.
One of the Phase II GVAX trials was designed to include 
hormone-naïve HRPC men with recurrent disease (after 
definitive surgery) and elevated PSA in the absence of 
radiologic metastatsis.92 There was a clinical immunologi-
cal response by PSA in the responder group suggesting that 
immune competence (defined as hormone/chemotherapy-
naïve patients) plays an important role in the timing of 
immunotherapy exposure. Evaluating the immune clinical 
responses and survival benefit in immunologically different 
populations (the rest of the GVAX trials included pretreated 
patients) does not seem to generate comparable results. 
Despite early promising results, including an instance of 
sharp PSA regression, later clinical trials were unable to 
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The VITAL-1 trial of GVAX vs docetaxel + prednisone 
(NCT00089856), limited to subjects with metastasis and 
without significant cancer-related pain, finished accrual 
(N = 626) but was ended with less than a 30% chance of 
meeting the overall survival primary endpoint. The accrual 
from the VITAL-2 trial of GVAX + docetaxel vs predni-
sone + docetaxel (NCT00133224) was stopped early due 
an excess of mortality on the investigational arm (67 vs 47; 
N = 408 accrued).93 It is not known whether a different dis-
ease subpopulation, or a different adjunctive treatment would 
result in a more useful anticancer immunotherapy. 
Although the immunologic basis for the absence of 
benefit could not be determined directly from the available 
clinical data, several theoretical details which contrast with 
sipuleucel-T can be considered: were the patients, overall, 
too advanced to have competent acquisition of new immunity, 
or conversely were the tumors too established, or too rapidly 
growing to respond to immune attack? Did the inclusion of 
glucocorticoid impede a useful vaccine response? Did the 
potential for tolerance emanating from exposure to alloge-
neic, cancer-irrelevant antigens crowd out the capacity for 
quantitative immune response to the relevant tumor antigens? 
Is it more difficult, in human disease, to simultaneously break 
tolerance for many antigens than for one?
immune modulation not connected  
to specific antigens
A variety of general immune modulators may be relevant 
to the challenge of generating clinically useful anticancer 
immune responses. One that is in advanced clinical develop-
ment is the anti-CTLA-4 antibody, ipilumimab (Yervey™, 
formerly MDX 010, Bristol-Myers Squibb, New York). The 
CTLA-4 cell surface molecule is on T lymphocytes and 
mediates lymphocyte downregulation following antigen-
specific activation and proliferation. Through attenuation of 
that response, anticancer activity may be increased. Among 
several prostate cancer directed studies addressing use in 
neoadjuvant, combination with GM-CSF, and combination 
with docetaxel, a Phase III randomized study (ipilumimab 
vs placebo) in post-docetaxel, CRPC has been initiated 
(NCT01057810). The experience of a positive Phase III 
trial in melanoma therapy was reported in 2010 and FDA 
approved March 2011,95 leading to considerable optimism 
for further development in other cancers as well.96
Overall, since many of these other immunotherapies 
rely on mechanisms that are potentially complementary to 
sipuleucel-T, there is hope that future combinations could 
amplify the anticancer impact.
Patient perspectives: adherence  
and acceptance
Defining goals of therapy
For any anticancer therapy, both physician and patient must 
understand the potential benefits and limitations. In many set-
tings, such as a radical prostatectomy, these can be defined in 
concrete terms: chance of cure, risk of urinary incontinence, 
erectile dysfunction, or other surgical complication. In that 
clinical setting, the feedback on these questions is almost 
immediate, in the days and weeks after the operation.
Among those patients with elevated PSA after definitive-
intent local therapy (mostly radiation and surgery), many 
have, at least initially, no other radiographically or clini-
cally identifiable disease. For those who have no specific 
anatomically identifiable metastasis, it is the PSA level that 
is the most accessible measure of disease response. The 
usual androgen suppression treatment approach gives an 
almost immediate feedback on the effect of treatment, vis-
ible as a fall of PSA, and potentially also a measurement of 
testosterone suppression.
While immediate feedback is gratifying, for both physi-
cian and patient, there remains a reality-check that is not 
always appreciated: PSA is not a toxic substance in itself. 
While most therapies’ treatment effect is visible as a PSA 
response, that may not translate directly into an impact on 
symptoms nor overall survival. Indeed, initial definitive local 
treatment of indolent prostate cancer is emerging as a para-
digm of a treatment with potential for more harm than good 
among elderly patients with comorbidities that represent a 
greater threat to overall survival. Algorithms to optimize 
an individualized assessment are evolving, and some are 
available, for example the Japan Cancer of the Prostate Risk 
Assessment (J-CAPRA) instrument.97
PSA vs OS
Looking at CRPC, there is now a potentially weaker direct 
connection between PSA changes and survival impact, both 
for individual and group experience. Most trials, especially 
docetaxel based studies, have suggested that treatment deci-
sions can be based on PSA patterns, particularly during drug 
development.98 PSA decrement and clinical benefit are closely 
connected in studies with docetaxel30,31 and cabazitaxel35 and 
the recently presented abiraterone data.45 However, two recent 
CRPC Phase III trials demonstrated a different pattern, with 
apparent benefit in controlling PSA and tumor size, but then 
with no overall survival benefit. A trial of satraplatin showed 
that for the time to pain progression, the hazard ratio (HR) 
improved significantly (0.64; 95% CI: 0.51 to 0.79; P , 0.001), OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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the PSA responses were higher more frequently (25.4 
vs 12.4%. P , 0.001), but no significant OS difference 
was observed (HR = 0.98, P , NS).37 The similarly sized 
(1001 patient) trial of docetaxel without or with bevaci-
zumab showed more PSA-response and tumor-responses 
in the combination arm (69.5 vs 57.9, P = 0.0002 [PSA] and 
53.2 vs 42.1, P = 0.0113 [objective response]), but still no 
significant OS impact (HR = 0.91, P = R 0.181, NS).36 With 
these experiences in mind, the distinction between short-term 
PSA impact and eventual OS can be better appreciated.
A disconnect has been observed, at least in one direction, 
in large, randomized experiences for a PSA-response, and 
progression-free survival/overall response (PFS vs OS). The 
question relevant to sipuleucel-T is: if there can be a PSA 
impact, but no survival impact for some drugs, can there be 
a survival impact, but no evident immediate disease impact 
for an immunotherapy? The most straightforward explana-
tion is that the latency of the anticancer effect is typically 
longer than the benchmark time point for PSA or progression 
assessment. For example, if maximum T-cell reactivity can 
take up to 10 weeks to achieve,70 early progression would 
not be a surprise finding.
For the aggregate sipuleucel-T trial data, this is a straight-
forward conclusion: the same result was observed across 
three randomized studies, and the review of the data, and 
the maturation of the data mandated by the US FDA sup-
port the conclusion that for the cohort of patients random-
ized to sipuleucel-T in the trials, a survival benefit of about 
4.1 months, at the median, was observed.
“PSA-believers”
For a prostate cancer patient who may have seen PSA 
response at prostatectomy, PSA response at initiation of 
testosterone suppression, PSA response with addition of 
bicalutamide, and PSA response with docetaxel + prednisone 
treatment, but is now presenting meeting nominal asymp-
tomatic CRPC criteria as were used in the pivotal trials of 
sipuleucel-T, how does one develop an expectation for the 
outcome of such therapy? The appeal of anticancer immuno-
therapy is enormous. Although sipuleucel-T is an autologous 
cellular product, the term “vaccine” projects a ready image of 
a rapid, holistic and protective response, such as a seasonal 
influenza vaccine. In contrast to a group analysis, as is usual 
for an individual’s isolated experience, there is no perspective 
on what difference in OS occurs.
We anticipate this will remain a question that is difficult 
to answer. Surely, some patients have more benefit, and 
some less. The extent to which an individual fits with the 
clinical features of the group that was studied 71 can increase 
the confidence of a treatment recommendation, but still falls 
short of a prediction that can be individualized. Indeed, the 
specific experience for the well-selected patient suggests an 
unsettling choice: if the PSA were rising, it would continue to 
rise if sipuleucel-T is used, or alternatively, it would continue 
to rise if sipuleucel-T is not used.
For the clinician faced with a making a medical recom-
mendation, the absence of early feedback on treatment 
response also has an unsettling parallel: for a patient whose 
clinical features do not match well those of the US FDA 
label or the pivotal trial, the same PSA pattern would be 
observed.
The pricing of Provenge™, at US$ 93,000 (wholesale) 
for the series of three infusions, naturally also creates a 
discussion point. For whom should such expenditure be 
justified? Most US patients will be reliant on third-party 
payer support for treatment, which can be anticipated to be 
relatively conservative with respect to alignment with the 
pivotal trial data.
Similar debates can be anticipated as any new drug is 
introduced. The high price of this, or other new cancer drugs 
(for example abiraterone is about US$ 50,000 a year and ipi-
lumimab about US$ 120,000 per course of four treatments) 
is one that puts the spotlight sharply on a balance of cost for 
a possible individual benefit vs the identifiable public ben-
efit. How closely must an individual duplicate the inclusion 
criteria of the pivotal trial? Where, when and for whom will 
the cost-per-survival increment meet a tipping point to deny 
coverage? Will that border be drawn on a “scientific” basis, 
or economically controlled?
Each national health policy and each insurer will evaluate 
treatments from a different perspective. Unfortunately, the 
established system precludes easy availability of sipuleucel-T 
to eligible patients, mostly due to the cost. There is an ongoing 
review of the pivotal study design, end points and outcomes 
with the purpose of justifying reimbursement by Centers for 
Medicare and Medicaid Services.98
Inevitably, differences in patterns of use in different 
insurance and economic settings, and national health 
policies and cultures can be anticipated. Factors such as 
Medicare coverage decision, entry of other (more conve-
nient) but expensive drugs (namely abiraterone in the last 
month), will influence both patients’ preferences and phy-
sician prescribing patterns. Construction of a sipuleucel-T 
production facility in Germany will define Europe as a 
new market. Ex-US sipuleucel-T availability depends on 
pending regulatory approval and overseas manufacturing OncoTargets and Therapy 2011:4
Table 2 examples of real life heterogeneity vs clinical trial criteria
“Too good” “Too bad” “Concurrent combinations”
Hormone-naïve prostate cancer, deferring  
hormone therapy, no metastatic disease
CRPC with metastasis, with significant pain  
symptoms, but they are well controlled  
with stable opiod regimen
Overlapping with docetaxel, during a PSA  
regression
Hormone-naïve prostate cancer, starting on  
hormone therapy with concurrent asymptomatic  
bone metastatic disease, identifying a high risk  
early of progression to CRPC
CRPC with prior progression through  
multiple lines of chemotherapy, such  
as both docetaxel and cabazitaxel
initially responding, but slowly breaking  
through ketoconazole + hydrocortisone
Previously hormone-responsive prostate  
cancer, no metastatic disease, slow rising PSA,  
considering addition of bicalutamide.
CRPC, asymptomatic, but with comorbid  
immunologic condition, such as chronic  
hepatitis C, but with no symptoms related  
to that
Concurrent with alternative or herbal  
medication, such as Prostasol™, after prior   
progression on conventional testosterone  
suppression
Abbreviations: CRPC, castrate-refractory prostate cancer; PSA, prostate specific antigen.
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infrastructure, before the hurdle of practical pricing can 
be addressed.
Disconnecting from the trial environment
For formal clinical trials, adherence to selection criteria is 
rigidly enforced, under the authority of scientific, regulatory, 
and institutional review boards (IRB); this is particularly so 
for a registration trial. The market experience is   different. 
Clinical heterogeneity in a real life oncology practice is 
substantial. For those individuals who would seem to be 
“beyond” the usual trial entry point, and thus, closer to death 
from disease, the compelling question is “why not now?” The 
safety experience did show a worse stroke event rate (23/338 
vs 3/168), which is still being evaluated in a post-marketing 
setting. The short term acute side effects of sipuleucel-T 
infusion are few, and the medical risk/benefit balance may 
still be positive for the vast majority of patients.
For those who are at a point in the disease course where 
the pivotal trial criteria would not be met, there is the ques-
tion: why should one be left “to ripen” until bad enough to 
meet criteria? On a theoretical immunologic basis, an indi-
vidual at an earlier point in the disease should have a better 
amplitude response, and maybe, better survival prospects. 
Empiric data on this issue of optimal timing are lacking. 
Some examples, drawn loosely from actual patient discus-
sions, are organized in Table 2.
Some patients will express an interest in sipuleucel-T 
therapy prior to testosterone suppression. This interest does 
not mean that the person misunderstood the selection criteria 
of the original trial, nor a conceptual difference on the under-
standing of hormone-sensitive versus refractory disease. It 
is, rather, a reflection of the heterogeneity of contemporary 
belief about the extent to which a rational, rather than strictly 
empiric, interpretation of new trial data should be used. 
Again, direct empiric data on this point are lacking.
education about the process of treatment
The chronology of a standard on-label treatment is annotated 
in Figure 1. The manufacturer’s website (www.provenge.
com) has a patient-directed video reviewing the process as 
well. There are a few points that merit emphasis in educating 
the patient about the treatment process, since it is so different 
from a conventional drug treatment.
The big first step is patient selection. Next is apheresis: 
the manufacturer has a defined set of approved leukaphere-
sis locations, and these may be quite a distance from the 
patient or the medical practice where the infusion is to take 
place. Since the apheresis bag is shipped out directly to 
the manufacturer, and then back to the infusion location, 
no transportation of any of the cellular material is by the 
patient; the patient must show up at the right places and 
times. The manufacturer’s schedule coordination program 
(“Dendreon On Call”) will set times for the collections and 
infusions; adherence to the schedule must be stressed. The 
apheresis center will also give guidance for the required 
caliber of intravenous access, which may vary based on 
available equipment. Some individuals will be able to use a 
pair of 16 gauge needles, placed at the center at the time of 
collection, but others, with marginal useful venous access, 
may require a separate placement of a vascular access 
device, such as a Hohn catheter, which will be in place 
for the entire month of the treatment and require periodic 
maintenance flushes. The leukapheresis process may take 
a couple of hours.
For each of the three infusions, the planned infusion time 
is 60 minutes, followed by at least 30 minutes observation. 
Each individual’s identity must be verified, and the specific 
quality control assessment completed. There is no assess-
ment for viral infections, underscoring the need for strictly 
autologous administration. If a quality control problem (for 
example cell count or bacterial contamination) were   identified OncoTargets and Therapy 2011:4
Sipuleucel-T infusions  #1, #2, #3
Apheresis #2
(collect cells primed 
on days 3–15) 
Medical
evaluation 
Apheresis
center
Placement
of IV access,
if needed
Billing & 
insurance
arrangements
Registration with
manufacturer
IV access, 
apheresis
& infusion
calendar
Infusion
center
After #3, remove IV access if necessary. 
Return for further care with PSA-, radiology- and 
clinically-based disease assessment and treatment.
Ship apheresis
for custom
manufacture Apheresis #1
~ 2 days from
apheresis to infusion
~14+ days between
aphereses
Apheresis #3
(collect cells primed 
on days 3–29) 
Dendreon® and Dendreon on call® logos are copyrighted symbols of Dendreon
Return for #2, #3
$?
Figure 1 Diagram of the treatment process. Starting in the lower left, is a patient consultation and medical evaluation. Continuing (upwards), registration with the Dendreon 
On Call program and defining practical third party payer issues. A treatment calender with line-placement (if needed), and three apheresis dates, each followed by infusion 
dates is developed. From there, the patient has a line placement (if needed), then 3 cycles of apheresis and infusion (illustrated by the clockwise arrows on the right). After 
the third infusion, the patient returns for consultation and further disease management.
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at a late point then that product must be set aside, and that 
portion of the apheresis/infusion cycle would need to be 
rescheduled. The window of time for the infusion is defined 
in strict terms, with only 3 hours allowed after removal from 
the shipping container, and a product expiration time speci-
fied based on the shipping time. A significant part of the shelf 
life could elapse during the shipping process, particularly if 
airport delays occur.
Patient information about side effects (as annotated at 
www.provenge.com) emphasize a high frequency of low 
grade chills (53%) fatigue (41%) and fever (31%) as well 
as 20%–30% with joint aches, nausea, or back aches.70 
Chills may result directly from the infusion of the 250 mL 
of cooled lactated Ringer’s, in which the cells are suspended 
(the sipuleucel-T should not be warmed, nor returned to 
the shipping container, but the patient may have a blanket). 
Delayed symptoms, such as from heart or lung reactions, 
should be managed directly, and considered to be potentially 
signs of infection.
Contrasting with other kinds  
of treatment
Referring to Figure 1, the step designated as the return to 
clinical consultation is a very real-world issue. After a month 
or so devoted to sipuleucel-T treatment, the clinician and the 
patient are back to the same treatment planning issues that 
brought them to the point of the sipuleucel-T   prescription. 
The administration of docetaxel after sipuleucel-T was 
relatively frequent in the pivotal trial experience. This does 
provide a specific base of experience for that sequence of 
treatment, although docetaxel itself was not, in a retrospec-
tive analysis, a factor on which the survival increment of 
sipuleucel-T was dependent.99
Beyond this, there is little specific guidance on a 
next active therapy. Outside a clinical trial, the reality is 
that no one individual could reliably discern a treatment 
effect, since the endpoint is overall survival. This may be 
an ongoing contrast with newer hormone therapies (such 
as MDV3100 or abiraterone), other immunotherapies or OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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newer   chemotherapies, all of which may afford some early, 
  accessible feedback, such as PSA levels. Patient acceptance 
of the concept of an isolated overall survival impact may be 
a moving target, influenced by features of other drugs, both 
in the immunotherapy and nonimmunotherapy classes.
Conclusion
Cancer immunotherapy achieved an important milestone with 
US FDA approval of sipuleucel-T. This cellular immuno-
therapy is a safe treatment option for prostate cancer, tested 
in minimally symptomatic CRPC patients with a median 
OS benefit of 4.1 months. Despite the lack of immediately 
evident antitumor effects, sipuleucel-T represents an excit-
ing prototype for future, more beneficial treatments with 
greater disease impact. From the early phase trials to the 
pivotal placebo-control trial with sipuleucel-T,71,73,77 the 
immunological outcomes, particularly the rising titer of 
antibodies with specificity to PA2024 and CTL titers, sug-
gest that further understanding can lead to amplification of 
the immunologic effect and clinical benefit.67 Even though 
sipuleucel-T trial data shows a survival improvement that 
is limited and comparable in size to benefits obtained 
with standard agents approved for this population,30,31 and 
cabazitaxel,35 it does not have the potential toxicity of che-
motherapy. Newer hormone-type therapies also have been 
shown to offer similar magnitude survival benefits (14.8 vs 
10.9 months for abiraterone).45
However, even as sipuleucel-T is the gateway to an excit-
ing new paradigm, the novel treatment still leaves unmet 
needs. The pivotal trial population was a narrowly defined 
one. Further studies are needed to determine other target 
populations, such as hormone sensitive disease, or subpopu-
lations defined by immunological parameters. These groups 
of men might be better candidates for immunotherapy, and 
a clinical response to immune modulation could be more 
clinically rewarding.
At this time, during the early use and expanding accep-
tance of sipuleucel-T, it is imperative to optimize the role 
and timing of sipuleucel-T for prostate cancer patient 
therapy. New agents both in hormone therapy and immu-
notherapy may also be expected to be part of a changing 
landscape for CRPC treatment. Sequencing and patient 
selection will be an evolving process, and we can be hopeful 
that more clinical trial participation will make sipuleucel-T 
a starting point for more quantitatively-effective, cost-
effective, well-tolerated treatment for the prostate cancer 
community.
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